Semin intervent Radiol 2011; 28(3): 288-295
DOI: 10.1055/s-0031-1284455
© Thieme Medical Publishers

Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Preprocedural Evaluation and Imaging

Abdullah M. S. Al-Osaimi1 , Saher S. Sabri2 , Stephen H. Caldwell1
  • 1Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia
  • 2Division of Interventional Radiology, Department of Radiology, University of Virginia Health System, Charlottesville, Virginia
Further Information

Publication History

Publication Date:
15 August 2011 (online)

ABSTRACT

Patients undergoing balloon retrograde transvenous obliteration (BRTO) are mostly decompensated cirrhotic with either bleeding gastric varices (GV) or hepatic encephalopathy. It is crucial that clinicians are up-to-date with the assessments needed prior to BRTO to anticipate and prevent complications, and to deliver critical quality care. These patients will require preprocedural assessments and management, including endoscopic, clinical, laboratory, and imaging evaluation. Endoscopic evaluation is mandatory prior to BRTO, and it is highly recommended that it be performed at the same institution where BRTO will be performed. It is essential that clinicians are aware of the potential benefits and complications that may result from BRTO. These complications should be anticipated and prevented when possible. For GV bleeders, there should be consideration of a transvenous intrahepatic portosystemic shunt (TIPS) during or before BRTO in patients with refractory ascites or pleural effusion, as well as endoscopic banding or a TIPS in patients with high-risk esophageal varices. Patients undergoing BRTO are usually complicated and require a team approach. In this article, the authors address these assessment and preparatory management and planning procedures prior to the BRTO procedure as well as expected outcomes and potential complications.

REFERENCES

  • 1 Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration.  J Gastroenterol Hepatol. 1996;  11 (1) 51-58
  • 2 Koito K, Namieno T, Nagakawa T, Morita K. Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals.  AJR Am J Roentgenol. 1996;  167 (5) 1317-1320
  • 3 Kitamoto M, Imamura M, Kamada K et al.. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage.  AJR Am J Roentgenol. 2002;  178 (5) 1167-1174
  • 4 Sakurabayashi S, Sezai S, Yamamoto Y, Hirano M, Oka H. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy.  Cardiovasc Intervent Radiol. 1997;  20 (2) 120-124
  • 5 Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy.  J Vasc Interv Radiol. 2001;  12 (3) 327-336
  • 6 Kravetz D, Bosch J, Arderiu M, Pilar Pizcueta M, Rodés J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting.  Hepatology. 1989;  9 (6) 808-814
  • 7 Castañeda B, Morales J, Lionetti R et al.. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats.  Hepatology. 2001;  33 (4) 821-825
  • 8 Villanueva C, Ortiz J, Miñana J et al.. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding.  Gastroenterology. 2001;  121 (1) 110-117
  • 9 de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension.  J Hepatol. 2005;  43 (1) 167-176
  • 10 Gabriel D A, Li X, Monroe III DMIII, Roberts H R. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.  J Thromb Haemost. 2004;  2 (10) 1816-1822
  • 11 Porte R J, Molenaar I Q, Begliomini B EMSALT Study Group et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study.  Lancet. 2000;  355 (9212) 1303-1309
  • 12 Tanabe N, Ishii M, Sato Y et al.. Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis.  Dig Dis Sci. 2000;  45 (3) 581-586
  • 13 Kumamoto M, Toyonaga A, Inoue H et al.. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome.  J Gastroenterol Hepatol. 2010;  25 (6) 1129-1135
  • 14 Takuma Y, Nouso K, Makino Y, Saito S, Shiratori Y. Prophylactic balloon-occluded retrograde transvenous obliteration for gastric varices in compensated cirrhosis.  Clin Gastroenterol Hepatol. 2005;  3 (12) 1245-1252
  • 15 Nakano R, Iwao T, Oho K, Toyonaga A, Tanikawa K. Splanchnic hemodynamic pattern and liver function in patients with cirrhosis and esophageal or gastric varices.  Am J Gastroenterol. 1997;  92 (11) 2085-2089
  • 16 Choi Y H, Yoon C J, Park J H, Chung J W, Kwon J W, Choi G M. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt.  Korean J Radiol. 2003;  4 (2) 109-116
  • 17 Kato T, Uematsu T, Nishigaki Y, Sugihara J, Tomita E, Moriwaki H. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis.  Intern Med. 2001;  40 (8) 688-691
  • 18 Akahane T, Iwasaki T, Kobayashi N et al.. Changes in liver function parameters after occlusion of gastrorenal shunts with balloon-occluded retrograde transvenous obliteration.  Am J Gastroenterol. 1997;  92 (6) 1026-1030
  • 19 Miyamoto Y, Oho K, Kumamoto M, Toyonaga A, Sata M. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension.  J Gastroenterol Hepatol. 2003;  18 (8) 934-942
  • 20 Cardoso J E, Gautreau C, Jeyaraj P R et al.. Augmentation of portal blood flow improves function of human cirrhotic liver.  Hepatology. 1994;  19 (2) 375-380
  • 21 Saad W, Darwish W, Anderson  et al.. The effect of balloon-occluded retrograde transvenous obliteration (BRTO) on the model of end-stage liver disease (MELD) score.  J Vasc Interv Radiol. 2011;  22 S34-S35
  • 22 Shimoda R, Horiuchi K, Hagiwara S et al.. Short-term complications of retrograde transvenous obliteration of gastric varices in patients with portal hypertension: effects of obliteration of major portosystemic shunts.  Abdom Imaging. 2005;  30 (3) 306-313
  • 23 Hiraga N, Aikata H, Takaki S et al.. The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration.  J Gastroenterol. 2007;  42 (8) 663-672
  • 24 Wada H, Hashizume M, Yamaga H, Kitano S, Sugimachi K. Hemodynamic and morphological changes in the dog kidney after injection of 5% ethanolamine oleate into the superior vena cava.  Eur Surg Res. 1990;  22 (2) 63-70
  • 25 Chikamori F, Shibuya S, Takase Y, Ozaki A, Fukao K. Transjugular retrograde obliteration for gastric varices.  Abdom Imaging. 1996;  21 (4) 299-303
  • 26 Kiyosue H, Mori H, Matsumoto S, Yamada Y, Hori Y, Okino Y. Transcatheter obliteration of gastric varices. Part 1. Anatomic classification.  Radiographics. 2003;  23 (4) 911-920
  • 27 Kiyosue H, Mori H, Matsumoto S, Yamada Y, Hori Y, Okino Y. Transcatheter obliteration of gastric varices: Part 2. Strategy and techniques based on hemodynamic features.  Radiographics. 2003;  23 (4) 921-937 discussion 937
  • 28 Chikamori F, Kuniyoshi N, Shibuya S, Takase Y. Eight years of experience with transjugular retrograde obliteration for gastric varices with gastrorenal shunts.  Surgery. 2001;  129 (4) 414-420
  • 29 Cho S K, Shin S W, Lee I H et al.. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients.  AJR Am J Roentgenol. 2007;  189 (6) W365-W372

Abdullah M. S. Al-OsaimiM.D. F.A.C.P. F.A.C.G. A.G.A.F. 

Associate Professor of Medicine and Surgery, Medical Director of Liver Transplantation, Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia Health System

P.O. BOX 800708, Charlottesville, VA 22908-0708

Email: aa6h@virginia.edu